After the era of block busters, mega mergers, and targeted therapeutics (Gleevec, Rituxan, etc.), pharma companies can now make use of new health technology to help patients benefit more from their treatments as we are shifting to outcome-based payment models. With tens of billions of dollars of drugs going off patent in the coming years, pharma companies have added pressure to take advantage of the opportunities that digital health technology offers. Innovation at both ends of the value chain can lead to better patient outcomes and better business results.Panelists from pharma, medical device companies, as well as Health 2.0 companies will address these and other questions in our first meeting of iPharma – the new innovation reshaping pharma’s future.  Please join us as we showcase companies who are leading the charge in bringing innovation to this field, and together brainstorm solutions you can take back to your team.

Sunday, October 7, 2012


Franciscan CD


Moderated by Marco Smit – President - Health 2.0 Advisors

President of Health 2.0 Advisors (the market intelligence branch of the Health 2.0 Empire) Marco Smit will give an overview of the changes in pharma from the digital technology perspective. Marco has been a heading up the Health 2.0 market intelligence business unit, which helps pharma companies with their growth / innovation needs, and previously worked with pharma companies as consultant (e.g. Genentech) and executive in partner companies (e.g. Affymetrix).


Franciscan CD

Innovations in Adherence

Moderated by Marco Smit – President - Health 2.0 Advisors

For patients, improving medication adherence can both bolster patients’ health as well as revenues. But pharma can’t help realize this objective on its own: adherence is a multi-stakeholder sport. Many of the innovations for adherence improvement are coming from outside of pharma...and sometimes aim to help payers (employers, insurance companies) or others whose incentives are not aligned with those of pharma companies


Franciscan CD

Clinical Trial Recruitment and Clinical Research Innovation

Phase III clinical trials typically represent 50-90 % of the cost of developing an individual drug, and their costs are rising fast. The FDA is also becoming more demanding post-approval for evidence that drugs are safe and provide clinical benefit. How can digital communications and patient engagement tools speed recruitment and improve trial outcomes? And how are the pioneering companies pushing the boundaries of what is possible and what gets done?


Tahir Mahmood
Booz Allen Hamilton